Edmond Pharma Srl manufactures active pharmaceutical ingredients. It develops patented product, managed from synthesis to Marketing authorization. The firm��s Erdosteine has a clinically supported efficacy in acute respiratory diseases and COPD (Chronic Obstructive Pulmonary Disease). The company was founded in 1970 and is headquartered in Masate, Italy.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. engages in the manufacture, sale, research and development of pharmaceutical products. Its products include anti-infective, antiviral, respiratory system, digestive system, nervous, endocrine, cardiovascular system, antipyretic, analgesics & anti-inflammatory, oncology, anti-allergic APIs & intermediates, lyophilized powder for injection preparation, solid preparation, chemical raw medicine, cephalosporin raw medicine and oral cephalosporin series. The company was founded on December 14, 1995 and is headquartered in Linyi, China.

DaebongLS Co., Ltd. engages in the manufacturing and distributing of raw materials for pharmaceuticals and cosmetics. It operates through the following business divisions: Cosmetics, Pharmaceuticals, and Food Additives. The Cosmetics division supplies conditioners, emollients, emulsifiers, permanent wave, and solubilizers. The Pharmaceuticals division offers raw materials used to prevent seizures, peptic ulcer, and hypertension. The Food Additives division provides aquacals, ascorbic acids, corn starches, fish, and folic oils. The company was founded by Jong-Ho Park on July 8, 1986 and is headquartered in Incheon, South Korea.

Qingdao Lanshengyang Pharmaceutical Biotechnology Co., Ltd., established on 2015-07-08, The scope of business includes the development of pharmaceutical biotechnology,technology transfer,technical consulting,Technology Promotion,Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beijing Rundekang Pharmaceutical Technology Co., Ltd., established on 2005-07-15, Business scope includes technology development;technology transfer;technical consulting;Technical Services;Import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Adcock Ingram Ltd. manufactures and markets pharmaceuticals, personal care, and household hygiene products. The firm's products are used in the areas of cardiovascular, central nervous system, dermatology, diabetes, ear, nose and eye preparations, feminine health, and analgesics. The company was founded in 1890 and is headquartered in Bryanston, South Africa.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

Hanseo Chemical Co., Ltd. is a South Korean private company that manufactures turbines.

ENZYCHEM LIFESCIENCES Corp. engages in developing, manufacturing, and distributing pharmaceutical products. Its main products include beta lactam antibiotics, non-beta lactam active pharmaceutical ingredient (APIs), and others. The beta lactam antibiotics include Cefazedone, Cefbuperazone and Ceftizoxime. The non-beta lactam APIs include D-cycloserine and Talniflumate. The company was founded on July 20, 1999 and is headquartered in Jecheon-si, South Korea.

Beijing Beipeng Technology Co., Ltd., established on 2007-06-29, Business scope includes technology development,technology transfer,technical consulting,Technical Services;Commissioned processing of chemical products(Removal of hazardous chemicals);sell cleaning supplies,cosmetic.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Wuhan Benjamin Pharmaceutical Co., Ltd., established on 2013-05-29, Business scope includes pharmaceutical,Research and development of chemical products;Chemical materials(Does not contain dangerous goods)research and development,Production,Sales;Import and export,Technology Import and Export,Agent import and export(Goods and technologies prohibited or restricted from import and export by the state are not included).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Qingdao Huazhicao Pharmaceutical Technology Co., Ltd., established on 2015-09-06, Business scope includes medical technology development,technical consulting,Technology Promotion,Technical Services;Operating other general business items that can be operated without administrative approval.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

infirst HEALTHCARE is a new consumer healthcare company focused on improving well established drugs with IP protected solutions for the OTC/Primary care markets which can be launched within 12-36 months. infirst is a spin-out from SEEK, a UK privately-owned drug discovery group which uses its intellectual property to create breakthrough medicines addressing major diseases, bringing radical improvements to human health. infirst is led by CEO, Manfred Scheske, who was previously President of GSK's US$3 billion European Consumer Healthcare business (including brands such as alli, Aquafresh, Beechams, Corsodyl, Lucozade, Niquitin, Panadol. Piriton, Poligrip, Ribena, Sensodyne, Solpadeine, Zantac and Zovirax) from 2004 to 2010 and also spent six years as President of GSK's Consumer Healthcare business in North America

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

KYUNG DONG PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of medicines for liver therapy, gastrointestinal, antimigrain, osteoporosis, cardiovascular, antiviral, antiobesity, muscle relaxant, neuropathic, antibacterial, antidiabetic, central nervous system, antifungal, urology, antispasmodic, pain and inflammation, antihistamine, vitamin, repiratory, antiinflammatory enzyme, respiratory and others. Its products include prescription medicine, over-the-counter drugs and active pharmaceutical ingredients. The company was founded on February 12, 1976 and is headquartered in Hwaseong-si, South Korea.

Hainan Yishun Pharmaceutical Co., Ltd., established on 2003-06-06, The business scope includes powder injection,Freeze-dried powder injection,Pills,API(Yanhuning,Propyl gallate,Sodium carbosulfonate)production and sales;Pharmaceutical packaging(Outer packaging only),food,cosmetic,Disinfectant,medical instruments(Limited to one category)Chinese herbal medicine(Does not contain precious medicinal materials)Sales;e-commerce;Investment Advisory;Research Consulting;Marketing Planning;Conference and Exhibition Services;technology transfer;information service;Travel services;Advertising Services;Commodity and technology import and export business(State regulations prohibit operating,Designated operation,Except for restricted goods and technologies).

Nantong Qiwu Agricultural Products Co., Ltd., established on 2007-04-19, The business scope includes other grain processing products(Peeled Broad Beans)processing,Sales.cereal,beans,potatoes,Oilseeds and Cotton Purchase,Sales,Import and export business of self-management and general business items and technology;The import and export business of commodities and technologies for licensed business projects must obtain special approval from the state before operating.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the United States, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.

J2H Biotech, Inc. is engaged in the manufacturing of Medicinal Chemicals and Antibiotics. The company was founded on October 1, 2014 and is headquartered in Suwon-si, South Korea.